Exogenous VIP limits zymosan-induced generalized inflammation (ZIGI) in mice.
Vasoactive intestinal peptide (VIP) was administered in a model of zymosan-induced generalized inflammation (ZIGI). Its beneficial action was associated with reduced TNF-alpha and increased IL-10 production, lowered levels of creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin in circulation. VIP diminished the level of RANTES and MIP-1alpha in peritoneal exudate and circulation. The neuropeptide inhibited NO release from stimulated peritoneal macrophages. Decreased spleen, liver and kidney enlargement and less pathological changes in liver were observed. The effect of VIP was attenuated by pretreatment with VIP antagonist (anti-VIP) before the induction of shock.
Ivanovska
Nina
N
Department of Immunology, Institute of Microbiology, 26 G. Bonchev Str., 1113 Sofia, Bulgaria. nina@microbio.bas.bg <nina@microbio.bas.bg>
Kalfin
Reni
R
Lazarova
Maria
M
Dimitrova
Petya
P
D000818:Animals; D016207:Cytokines / Q000097:blood / Q000276:immunology / Q000378:metabolism*; D007249:Inflammation / Q000097:blood / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D018836:Inflammation Mediators / Q000097:blood / Q000276:immunology / Q000378:metabolism*; D017737:Macrophages, Peritoneal / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009929:Organ Size / Q000276:immunology; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D015054:Zymosan / Q000008:administration & dosage / Q000097:blood / Q000276:immunology*
D016207:Cytokines; D018836:Inflammation Mediators; D014660:Vasoactive Intestinal Peptide; D015054:Zymosan